Abstract:
:The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advancements in interpretation of variants of unknown significance to maximize clinical benefit. Nevertheless, personalized sequencing, only recently applied to clinical medicine, has already been broadly applied to the discovery and study of disease. It is poised to enable the earlier and more accurate diagnosis of disease risk and occurrence, guide prevention and individualized intervention as well as facilitate monitoring of healthy and treated patients, and play a role in the prevention and recurrence of future disease. This article documents the advancing capacity of personalized sequencing, reviews its impact on disease-oriented scientific discovery and anticipates its role in the future of medicine.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Esplin ED,Oei L,Snyder MPdoi
10.2217/pgs.14.117subject
Has Abstractpub_date
2014-11-01 00:00:00pages
1771-1790issue
14eissn
1462-2416issn
1744-8042journal_volume
15pub_type
杂志文章相关文献
PHARMACOGENOMICS文献大全abstract:AIM:This study evaluated the impact of SULT4A1 gene variation on psychopathology and antipsychotic drug response in Caucasian subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and a replication sample. PATIENTS & METHODS:SULT4A1 haplotypes were determined using SNP data. The r...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.205
更新日期:2011-04-01 00:00:00
abstract::The first observations of inherited differences in drug effects in the 1950s led to the recognition of a genetic basis for drug response. With the development of genetics and molecular biology, it became clear that certain drug responses could be associated with specific genetic variations or polymorphisms. There are ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.4.453
更新日期:2002-07-01 00:00:00
abstract::The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/14622416.5.7.895
更新日期:2004-10-01 00:00:00
abstract:BACKGROUND:Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM:The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response t...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.119
更新日期:2014-09-01 00:00:00
abstract:AIM:Cytidine deaminase (CDA) irreversibly deaminates cytarabine (Ara-C), a key component of acute myeloid leukemia (AML) induction and consolidation therapy. CDA overexpression results in Ara-C resistance, while decreased expression is associated with toxicity. We evaluated factors influencing variation in CDA mRNA exp...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.149
更新日期:2012-02-01 00:00:00
abstract::The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.7.5.759
更新日期:2006-07-01 00:00:00
abstract::Biobanking became a necessity for translating genetic discoveries into clinical practice. Approaches to personalized medicine require a new model system for functional and pharmacogenomic studies of a variety of accumulating genetic variations, as well as new research environments such as biobankomics. Human lymphobla...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.24
更新日期:2011-06-01 00:00:00
abstract:INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/14622416.6.3.293
更新日期:2005-04-01 00:00:00
abstract::Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2020-0056
更新日期:2020-11-01 00:00:00
abstract:AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.17
更新日期:2010-05-01 00:00:00
abstract:AIM:We aimed to understand consent practices for pharmacogenetic (PGx) testing. METHODS:We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing. RESULTS:Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0039
更新日期:2016-09-01 00:00:00
abstract::Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.12.113
更新日期:2012-09-01 00:00:00
abstract::Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.6.5.503
更新日期:2005-07-01 00:00:00
abstract:AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2217/pgs.13.145
更新日期:2013-10-01 00:00:00
abstract:BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,随机对照试验
doi:10.2217/pgs.14.167
更新日期:2015-01-01 00:00:00
abstract:AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.98
更新日期:2015-01-01 00:00:00
abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,评审
doi:10.2217/pgs.12.159
更新日期:2012-11-01 00:00:00
abstract:AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.247
更新日期:2014-03-01 00:00:00
abstract::Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.7.3.395
更新日期:2006-04-01 00:00:00
abstract:AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章
doi:10.2217/pgs.10.51
更新日期:2010-06-01 00:00:00
abstract::Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0023
更新日期:2016-06-01 00:00:00
abstract::Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0192
更新日期:2018-04-01 00:00:00
abstract::Drugs used to treat psychiatric disorders, even when taken as directed, fail to provide adequate relief for a sizeable proportion of patients. Despite our advancements in understanding human genetics and development of high-throughput tools to probe variation, pharmacogenomics has yielded marginal ability to predict d...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2017-0104
更新日期:2017-10-01 00:00:00
abstract::The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.3.349
更新日期:2008-03-01 00:00:00
abstract:AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.96
更新日期:2015-01-01 00:00:00
abstract:AIM:CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous populations. Thus, frequencies of CYP2C9*2 and CYP2C9*3 alleles were evaluated in indigenous groups located in northwest (Cora), center (Mazahua an...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2016-0099
更新日期:2016-11-01 00:00:00
abstract::Many biomarkers indicate prognosis in chronic lymphocytic leukemia; such as fluorescence in situ hybridization testing: 17p or 11q deletions have a worse prognosis than trisomy 12, 13q deletion or normal result, or the mutational status of the immunoglobulin heavy chain (IGHV): unmutated IGHV have a worse prognosis th...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2020-0022
更新日期:2020-08-01 00:00:00
abstract::RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.1.2.187
更新日期:2000-05-01 00:00:00
abstract:AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.10.2.277
更新日期:2009-02-01 00:00:00
abstract:UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.132
更新日期:2010-01-01 00:00:00